Anthos Therapeutics, Inc.
6 clinical trials · Sponsor
◉ Watch Anthos Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) (NCT05712200) | Anthos Therapeutics, Inc. | 2022-12-27 |
| A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE (NCT05171075) | Anthos Therapeutics, Inc. | 2022-09-27 |
| Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke (NCT05421533) | Anthos Therapeutics, Inc. | 2022-09-14 |
| Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation (NCT04755283) | Anthos Therapeutics, Inc. | 2021-02-02 |
| A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation (NCT04213807) | Anthos Therapeutics, Inc. | 2019-12-11 |
Track Anthos Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.